These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
41 related articles for article (PubMed ID: 2399513)
21. The effect of obesity on acetaminophen pharmacokinetics in man. Lee WH; Kramer WG; Granville GE J Clin Pharmacol; 1981 Jul; 21(7):284-7. PubMed ID: 7263926 [TBL] [Abstract][Full Text] [Related]
22. Percutaneous absorption of dexamethasone acetate and palmitate, and the plasma concentration. Ogiso T; Ito Y; Iwaki M; Atago H; Tanaka C; Maniwa N; Ishida S Chem Pharm Bull (Tokyo); 1987 Oct; 35(10):4263-70. PubMed ID: 3435951 [No Abstract] [Full Text] [Related]
23. Glucocorticoids dosing in obese subjects: A systematic review. Delaleu J; Destere A; Hachon L; Declèves X; Lloret-Linares C Therapie; 2019 Sep; 74(4):451-458. PubMed ID: 30928086 [TBL] [Abstract][Full Text] [Related]
25. Drug dosing in hospitalized obese patients with COVID-19. Barletta JF; Erstad BL Crit Care; 2022 Mar; 26(1):60. PubMed ID: 35287690 [TBL] [Abstract][Full Text] [Related]
26. Dexamethasone attenuates the embryotoxic effect of endometriotic peritoneal fluid in a murine model. Heitmann RJ; Tobler KJ; Gillette L; Tercero J; Burney RO J Assist Reprod Genet; 2015 Sep; 32(9):1317-23. PubMed ID: 26198138 [TBL] [Abstract][Full Text] [Related]
27. Demographics, assessment and management of pain in the elderly. Davis MP; Srivastava M Drugs Aging; 2003; 20(1):23-57. PubMed ID: 12513114 [TBL] [Abstract][Full Text] [Related]
28. Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. Caraco Y; Zylber-Katz E; Berry EM; Levy M Eur J Clin Pharmacol; 1995; 47(6):525-30. PubMed ID: 7768256 [TBL] [Abstract][Full Text] [Related]
29. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. Cheymol G; Weissenburger J; Poirier JM; Gellee C Br J Clin Pharmacol; 1995 Jun; 39(6):684-7. PubMed ID: 7654489 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of sufentanil in obese patients. Schwartz AE; Matteo RS; Ornstein E; Young WL; Myers KJ Anesth Analg; 1991 Dec; 73(6):790-3. PubMed ID: 1835321 [TBL] [Abstract][Full Text] [Related]
31. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Varis T; Kivistö KT; Backman JT; Neuvonen PJ Clin Pharmacol Ther; 2000 Nov; 68(5):487-94. PubMed ID: 11103751 [TBL] [Abstract][Full Text] [Related]
32. Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Ness-Abramof R; Nabriski D; Apovian CM; Niven M; Weiss E; Shapiro MS; Shenkman L Obes Res; 2002 Dec; 10(12):1217-21. PubMed ID: 12490665 [TBL] [Abstract][Full Text] [Related]